• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

DNA 甲基化组分析揭示了潜在的改变,这些改变可能导致支气管增生的进展。

DNA methylome analysis reveals potential alterations contributing to the progression of bronchial hyperplasia.

机构信息

Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia.

National Research Tomsk State University, Tomsk, Russia.

出版信息

Mol Biol Rep. 2023 Sep;50(9):7941-7947. doi: 10.1007/s11033-023-08571-6. Epub 2023 Jul 22.

DOI:10.1007/s11033-023-08571-6
PMID:37480511
Abstract

BACKGROUND

Squamous cell lung cancer (SCLC) arises from bronchial changes: basal cell hyperplasia (BCH), squamous metaplasia (SM), and dysplasia. However, the premalignant process preceding SCLC is not inevitable; it can stop at any of the bronchial lesions. Previously, we hypothesized that combinations of premalignant lesions observed in the small bronchi of SCLC patients can reflect the different "scenarios" of the premalignant process: BCH-the stoppage at the stage of hyperplasia and BCH-the progression of hyperplasia to metaplasia.

METHODS AND RESULTS

In this study, using whole-genome bisulfite sequencing we analyzed the DNA methylome of two forms of BCH: isolated BCH (BCH) and BCH co-occurred with SM (BCH) in the small bronchi of SCLC patients. It was shown that BCH harbored differentially methylated regions (DMRs) affecting genes associated with regulating phosphatase activity. In BCH, DMRs were found in genes involved in PI3K-Akt and AMPK signaling pathways. DMRs were also found to affect specific miRNA genes: miR-34a and miR-3648 in BCH and miR-924 and miR-100 in BCH.

CONCLUSIONS

Thus, this study demonstrated the significant changes in DNA methylome between the isolated BCH and BCH combined with SM. The identified epigenetic alterations may underlie different "scenarios" of the premalignant process in the bronchial epithelium.

摘要

背景

鳞状细胞肺癌(SCLC)源自支气管改变:基底细胞增生(BCH)、鳞状化生(SM)和发育不良。然而,SCLC 之前的癌前病变过程并非不可避免;它可以在任何支气管病变处停止。此前,我们假设在 SCLC 患者的小支气管中观察到的癌前病变组合可以反映癌前病变过程的不同“场景”:BCH-在增生阶段停止和 BCH-增生向化生的进展。

方法和结果

在这项研究中,我们使用全基因组亚硫酸氢盐测序分析了两种形式的 BCH 的 DNA 甲基组:孤立的 BCH(BCH)和 BCH 与 SCLC 患者小支气管中的 SM 共存(BCH)。结果表明,BCH 具有影响调节磷酸酶活性相关基因的差异甲基化区域(DMR)。在 BCH 中,DMR 存在于参与 PI3K-Akt 和 AMPK 信号通路的基因中。DMR 还被发现影响特定的 miRNA 基因:BCH 中的 miR-34a 和 miR-3648 以及 BCH 中的 miR-924 和 miR-100。

结论

因此,这项研究表明孤立的 BCH 和与 SM 结合的 BCH 之间的 DNA 甲基组发生了显著变化。所确定的表观遗传改变可能是支气管上皮不同“场景”的癌前病变过程的基础。

相似文献

1
DNA methylome analysis reveals potential alterations contributing to the progression of bronchial hyperplasia.DNA 甲基化组分析揭示了潜在的改变,这些改变可能导致支气管增生的进展。
Mol Biol Rep. 2023 Sep;50(9):7941-7947. doi: 10.1007/s11033-023-08571-6. Epub 2023 Jul 22.
2
Analysis of Methylome of Different Forms of Basal Cell Hyperplasia and Squamous Cell Metaplasia of Bronchial Epithelium.分析支气管上皮不同形式的基底细胞增生和鳞状上皮化生的甲基组。
Bull Exp Biol Med. 2024 May;177(1):93-97. doi: 10.1007/s10517-024-06138-4. Epub 2024 Jul 4.
3
Gene Expression Profiling Revealed 2 Types of Bronchial Basal Cell Hyperplasia and Squamous Metaplasia With Different Progression Potentials.基因表达谱揭示了具有不同进展潜能的两种支气管基底细胞增生和鳞状化生类型。
Appl Immunohistochem Mol Morphol. 2020 Jul;28(6):477-483. doi: 10.1097/PAI.0000000000000762.
4
Recurrence of squamous cell lung carcinoma is associated with the co-presence of reactive lesions in tumor-adjacent bronchial epithelium.肺鳞状细胞癌的复发与肿瘤相邻支气管上皮中反应性病变的共存有关。
Tumour Biol. 2016 Mar;37(3):3599-607. doi: 10.1007/s13277-015-4196-2. Epub 2015 Oct 11.
5
Neoadjuvant chemotherapy combined with intraoperative radiotherapy is effective to prevent recurrence in high-risk non-small cell lung cancer (NSCLC) patients.新辅助化疗联合术中放疗可有效预防高危非小细胞肺癌(NSCLC)患者复发。
Transl Lung Cancer Res. 2020 Aug;9(4):988-999. doi: 10.21037/tlcr-19-719.
6
Premalignant Changes in the Bronchial Epithelium Are Prognostic Factors of Distant Metastasis in Non-Small Cell Lung Cancer Patients.支气管上皮的癌前病变是非小细胞肺癌患者远处转移的预后因素。
Front Oncol. 2021 Nov 10;11:771802. doi: 10.3389/fonc.2021.771802. eCollection 2021.
7
Microscopic analysis of the chromium content in the chromium-induced malignant and premalignant bronchial lesions of the rat.大鼠铬诱导的恶性和癌前支气管病变中铬含量的显微镜分析。
Environ Res. 2005 Oct;99(2):267-72. doi: 10.1016/j.envres.2004.10.001. Epub 2004 Dec 15.
8
Premalignant lesions of squamous cell carcinoma of the lung: The molecular make-up and factors affecting their progression.肺癌鳞状细胞癌前病变:分子构成及影响其进展的因素。
Lung Cancer. 2019 Sep;135:21-28. doi: 10.1016/j.lungcan.2019.07.001. Epub 2019 Jul 5.
9
Hyaluronidases and hyaluronan synthases expression is inversely correlated with malignancy in lung/bronchial pre-neoplastic and neoplastic lesions, affecting prognosis.透明质酸酶和透明质酸合酶的表达与肺/支气管癌前病变和肿瘤性病变的恶性程度呈负相关,影响预后。
Braz J Med Biol Res. 2015 Nov;48(11):1039-47. doi: 10.1590/1414-431X20154693. Epub 2015 Aug 28.
10
Basal layer reactivity in hyperplastic and metaplastic lesions of the bronchi as studied by lectin histochemistry.通过凝集素组织化学研究支气管增生性和化生性病损中的基底层反应性。
Lung. 2000;178(2):81-90. doi: 10.1007/s004080000011.

引用本文的文献

1
Premalignant Progression in the Lung: Knowledge Gaps and Novel Opportunities for Interception of Non-Small Cell Lung Cancer. An Official American Thoracic Society Research Statement.肺部癌前进展:非小细胞肺癌干预的知识空白和新机遇。美国胸科学会官方研究声明。
Am J Respir Crit Care Med. 2024 Sep 1;210(5):548-571. doi: 10.1164/rccm.202406-1168ST.
2
Specific association of expressions with small cell lung cancer development and chemoradiotherapy outcome.与小细胞肺癌发生和放化疗疗效相关的特定表达。
Saudi Med J. 2024 Aug;45(8):783-790. doi: 10.15537/smj.2024.45.8.20230990.

本文引用的文献

1
Hypomethylation of RPTOR in peripheral blood is associated with very early-stage lung cancer.外周血中RPTOR的低甲基化与极早期肺癌相关。
Clin Chim Acta. 2022 Dec 1;537:173-180. doi: 10.1016/j.cca.2022.10.014. Epub 2022 Nov 1.
2
Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials.肺鳞状细胞癌中的信号通路和靶向治疗:机制和临床试验。
Signal Transduct Target Ther. 2022 Oct 5;7(1):353. doi: 10.1038/s41392-022-01200-x.
3
Signal pathways and precision therapy of small-cell lung cancer.
小细胞肺癌的信号通路与精准治疗。
Signal Transduct Target Ther. 2022 Jun 15;7(1):187. doi: 10.1038/s41392-022-01013-y.
4
Premalignant Changes in the Bronchial Epithelium Are Prognostic Factors of Distant Metastasis in Non-Small Cell Lung Cancer Patients.支气管上皮的癌前病变是非小细胞肺癌患者远处转移的预后因素。
Front Oncol. 2021 Nov 10;11:771802. doi: 10.3389/fonc.2021.771802. eCollection 2021.
5
Genome wide DNA methylation analysis of alveolar capillary dysplasia lung tissue reveals aberrant methylation of genes involved in development including the FOXF1 locus.对肺泡毛细血管发育不良肺组织的全基因组 DNA 甲基化分析显示,包括 FOXF1 基因座在内的发育相关基因出现异常甲基化。
Clin Epigenetics. 2021 Jul 29;13(1):148. doi: 10.1186/s13148-021-01134-1.
6
MicroRNA-34a: Potent Tumor Suppressor, Cancer Stem Cell Inhibitor, and Potential Anticancer Therapeutic.微小RNA-34a:强效肿瘤抑制因子、癌症干细胞抑制剂及潜在的抗癌治疗手段
Front Cell Dev Biol. 2021 Mar 8;9:640587. doi: 10.3389/fcell.2021.640587. eCollection 2021.
7
Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas.从癌前病变到浸润性肺腺癌的 DNA 甲基组演变。
Nat Commun. 2021 Jan 29;12(1):687. doi: 10.1038/s41467-021-20907-z.
8
MiR-924 as a tumor suppressor inhibits non-small cell lung cancer by inhibiting RHBDD1/Wnt/β-catenin signaling pathway.作为肿瘤抑制因子的MiR-924通过抑制RHBDD1/Wnt/β-连环蛋白信号通路来抑制非小细胞肺癌。
Cancer Cell Int. 2020 Oct 8;20:491. doi: 10.1186/s12935-020-01516-0. eCollection 2020.
9
microRNA-100 functions as a tumor suppressor in non-small cell lung cancer via regulating epithelial-mesenchymal transition and Wnt/β-catenin by targeting HOXA1.miRNA-100 通过靶向 HOXA1 调控上皮-间充质转化和 Wnt/β-catenin 通路发挥抑癌作用在非小细胞肺癌中
Thorac Cancer. 2020 Jun;11(6):1679-1688. doi: 10.1111/1759-7714.13459. Epub 2020 May 4.
10
Lung Cancer 2020: Epidemiology, Etiology, and Prevention.肺癌 2020:流行病学、病因学和预防。
Clin Chest Med. 2020 Mar;41(1):1-24. doi: 10.1016/j.ccm.2019.10.001.